Clinical trial NCT00768768: Iontophoretic Application of Terbinafine Gel to the Large Toe Nail
Official title: A Study of Skin/Nail Sensation and the Pharmacokinetics of the Uptake of Terbinafine in the Great Toe Nail and Systemically Following Treatment With the Electrokinetic Transungual System (ETS)-Terbinafine Gel in Healthy Normal Voluneteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Onychomycosis
Keywords: iontophoresis
terbinafine
onychomycosis
Lead sponsor: Transport Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2008-10-08
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Terbinafine is recognized as one of the most effective drugs for the treatment of toe nail fungus (onychomycosis). This trial will be the first test of a new device to improve the delivery of terbinafine directly to the toe nail. The device uses a low level of electric current, iontophoresis, to "push" the terbinafine into the nail.

The study will involve a single application of terbinafine, in a gel form, with the iontophoretic device. The treatment will be applied to the surface of both large toenails of healthy subjects. Subjects will be asked to report any sensations in the nail or surrounding skin experienced during or after treatment. Samples from the edge of the treated toe nail will be taken at 2-4 week intervals to measure how much terbinafine was delivered to the nails, and blood samples will be taken for the first 24 hours after treatment to determine how much, if any, terbinafine was absorbed into the subjects's body. Observations will also be made of the treated toes to look for any irritation of the surrounding skin due to the treatment.


Eligibility criteria: Inclusion Criteria:

* Male and female volunteers between 18 and 75 years of age, inclusive.

Exclusion Criteria:

* Subjects with pacemakers or automatic implantable cardioverter/defibrillator
* Subjects with an implantable electronic device.
* Subjects with a history of diabetes.
* Subjects with a history of onychomycosis or an abnormal appearing nail on the great toe
* Subject using systemic antifungal medications within 6 months prior to study enrollment.
* Subject using prescription topical antifungal medications for toenail fungus within 3 months or other commercially available medications for toenail fungus applied directly to the toenail within 1 week prior to study enrollment.
* Subject with a history of allergic or adverse response to terbinafine or any related anti-fungal drug
* Participation in a previous clinical trial involving an investigational drug or device within 30 days prior to study enrollment.
* Subject requires chronic use of analgesics, pain medication, or non-steroidal anti-inflammatory agents (NSAIDS).
* In females of childbearing potential, a positive urine pregnancy test at screening and just prior to dosing.
* Nursing mothers.
* Subject with a history of alcoholism or drug abuse within the preceding 12 months.

Primary outcomes:
measure: Evaluate the skin/nail sensation noted by subjects during and following iontophoretic application of terbinafine gel to the great toenail
timeFrame: 12 weeks
Secondary outcomes:
measure: Evaluate the uptake into the nail of the great toe and the systemic uptake and pharmacokinetics of terbinafine following a single iontophoretic application of terbinafine gel
timeFrame: 12 weeks and 24 hours, respectively
Other outcomes:
Locations:
city: Fargo
country: United States
facility: Cetero Research
state: North Dakota
Study officials:
affiliation: Cetero Research, San Antonio
name: Craig Sprenger, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Transport Pharmaceuticals, Inc.
name: Eric M Morrel, PhD
role: STUDY_DIRECTOR
affiliation: Transport Pharmaceuticals, Inc.
name: Philip M Friden, PhD
role: STUDY_DIRECTOR
References: